BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 27654293)

  • 1. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).
    Gaymard A; Charles-Dufant A; Sabatier M; Cortay JC; Frobert E; Picard C; Casalegno JS; Rosa-Calatrava M; Ferraris O; Valette M; Ottmann M; Lina B; Escuret V
    J Antimicrob Chemother; 2016 Nov; 71(11):3036-3045. PubMed ID: 27432605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
    Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
    Stoner TD; Krauss S; DuBois RM; Negovetich NJ; Stallknecht DE; Senne DA; Gramer MR; Swafford S; DeLiberto T; Govorkova EA; Webster RG
    J Virol; 2010 Oct; 84(19):9800-9. PubMed ID: 20660186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
    Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
    Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
    Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
    Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
    Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
    Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.
    Burnham AJ; Armstrong J; Lowen AC; Webster RG; Govorkova EA
    J Virol; 2015 Apr; 89(8):4575-87. PubMed ID: 25673705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
    Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
    J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
    Hoffmann A; Schade D; Kirchmair J; Clement B; Sauerbrei A; Schmidtke M
    J Virol Methods; 2016 Nov; 237():192-199. PubMed ID: 27659246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
    Pizzorno A; Bouhy X; Abed Y; Boivin G
    J Infect Dis; 2011 Jan; 203(1):25-31. PubMed ID: 21148493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
    Prachanronarong KL; Özen A; Thayer KM; Yilmaz LS; Zeldovich KB; Bolon DN; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Kurt-Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2016 Dec; 12(12):6098-6108. PubMed ID: 27951676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
    Puzelli S; Facchini M; Di Martino A; Fabiani C; Lackenby A; Zambon M; Donatelli I
    Antiviral Res; 2011 Jun; 90(3):205-12. PubMed ID: 21514326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
    Song MS; Marathe BM; Kumar G; Wong SS; Rubrum A; Zanin M; Choi YK; Webster RG; Govorkova EA; Webby RJ
    J Virol; 2015 Nov; 89(21):10891-900. PubMed ID: 26292325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.